Peptide Library

Human study PLS-00050

Insights into the Biomarker Potential of Humanin and Mots-c Expression and Telomere Length in Alzheimer's Disease.

Case-control study · Not reported participants enrolled · not included in the assessments (other)

Version 1 · published November 7, 2026 · evidence through November 7, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

Only the abstract was available. Essential methods may be missing, which limits what can be judged.

Reports of this study

Every publication, registration and abstract describing this one study. Participants are counted once.

  • Insights into the Biomarker Potential of Humanin and Mots-c Expression and Telomere Length in Alzheimer's Disease.primary · International journal of molecular sciences · 2025-11-09 · PMID 41303353 · DOI

Design and participants

Design
Case-control study
Population
Patients with Alzheimer's disease and mild cognitive impairment, with individuals with subjective cognitive decline as controls.
Conditions
Alzheimer's disease, Mild cognitive impairment, Subjective cognitive decline
Planned enrollment (registry)
Not reported
Enrolled
Not reported
Randomized
Not reported
Completed follow-up
Not reported

Intervention and comparator

What each group received. Related peptides, analogs and combinations are never treated as the compound itself.

    What the authors reported

    As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.

    Adverse events

    None reported. That is not evidence of safety, and how safety was monitored isn’t described.

    The authors concluded (paraphrased): Blood and plasma transcript levels of humanin and MOTS-c, but not circulating protein levels, were reduced in Alzheimer's disease compared with subjective cognitive decline. The authors suggest these peptides may be early biomarkers of Alzheimer's disease.

    Peptide Library’s assessment

    An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.

    Limitations

    • other: MOTS-c was measured only as an endogenous biomarker and was never administered, so the study gives no evidence on effects of the compound.
    • abstract only: Only the abstract is available in the record; sample sizes, methods and numeric results are not reported.
    • inappropriate endpoint: Endogenous peptide expression is a biomarker. No MOTS-c was given, so the study says nothing about the effects or safety of administering it.
    • inappropriate population: Participants had cognitive impairment or decline, not obesity, insulin resistance or diabetes.

    No risk-of-bias assessment has been published for this study’s results.

    Claims this study informs

    Where each value comes from

    • author_conclusion: PMID 41303353, abstract (final sentence) · extracted by AI (automated, not verified by a person) · abstract only
    • design: PMID 41303353, abstract (sentence 4) · extracted by AI (automated, not verified by a person) · abstract only
    • population: PMID 41303353, abstract (sentence 4) · extracted by AI (automated, not verified by a person) · abstract only

    • Version 1 · published November 7, 2026 · evidence through November 7, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

    These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).